Loading…
ALX Oncology Holdings Inc. is projected to rise to $2.51 by 2027, a +18% move from its current price of $2.13. ALXO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.02 | $2.13 | $2.24 | +0.14% |
| Jul 13 | $1.98 | $2.13 | $2.29 | +0.27% |
| Jul 14 | $1.95 | $2.13 | $2.33 | +0.41% |
| Jul 15 | $1.93 | $2.14 | $2.37 | +0.54% |
| Jul 16 | $1.91 | $2.14 | $2.40 | +0.68% |
| Jul 17 | $1.89 | $2.14 | $2.43 | +0.81% |
| Jul 18 | $1.88 | $2.15 | $2.45 | +0.95% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.88 | $2.15 | $2.45 | +0.95% |
| Week 2 | $1.79 | $2.17 | $2.62 | +1.91% |
| Week 3 | $1.73 | $2.19 | $2.76 | +2.88% |
| Week 4 | $1.69 | $2.21 | $2.89 | +3.85% |
| Week 5 | $1.65 | $2.23 | $3.01 | +4.84% |
| Week 6 | $1.62 | $2.25 | $3.13 | +5.83% |
| Week 7 | $1.59 | $2.27 | $3.24 | +6.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies for cancer patients in the United States. Its lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic developed as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.
The company has collaboration agreements for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University.
The company was incorporated in 2015 and is headquartered in South San Francisco, California.
ALX Oncology Holdings Inc. (ALXO) trades at $2.06, with a market capitalization of $277.2M, and holds the 3,592nd rank by market cap. The stock sits in a landscape of small-cap biopharma with a focused immuno-oncology portfolio centered on Evorpacept and associated collaboration programs.
The current price sits within a forecast that shows a broad upside potential over the coming years. The projected average price for 2026 is $2.06, rising through the late 2020s to $3.92 by 2033 and climbing to $10.05 on average by 2050, with substantial upside implied by higher-year averages. The outlook includes a wide range of possible outcomes and sizable long-term upside, including a simulated ROI of up to 388% by 2050.
A major floor 54.1% below — a decisive break under it would weaken the trend.
The nearest floor, 35.1% below — buyers have tended to step in here.
The nearest ceiling, 11.1% above — a clean break opens room to run.
A major ceiling 38.1% above — clearing it would confirm fresh momentum.
Key ALXO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALXO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.21 | Sell | $2.16 | Sell |
| MA 10 | $2.15 | Sell | $2.10 | Buy |
| MA 20 | $1.88 | Buy | $1.98 | Buy |
| MA 50 | $1.86 | Buy | $1.89 | Buy |
| MA 100 | $1.94 | Buy | $1.84 | Buy |
| MA 200 | $1.75 | Buy | $1.76 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.76 | Neutral |
| Stoch RSI (14) | 42.91 | Neutral |
| CCI (20) | 60.48 | Neutral |
| Williams %R (14) | -32.19 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | 20.74 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 67.81 | Neutral |
| TRIX (15) | 0.68 | Buy |
| Awesome (5,34) | 0.39 | Buy |
| Ultimate (7,14,28) | 58.75 | Neutral |
| Momentum (10) | 0.34 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 2.23 | Sell |
| ADX (14) | 24.38 | Buy |
| ATR (14) | 0.09 | Info |
The 30-day technical picture is bullish in sentiment, with RSI(14) at 60 and near-neutral momentum indicators. The 50-day simple moving average stands at $1.85 and the 200-day average at $1.74, suggesting a potential drift toward the near-term resistance.
Key price levels define a near-term framework: support at $1.38 and resistance at $2.36. The 30-day price range spans from a low of $1.46 to a high of $2.90, illustrating a channel within which the stock has traded recently.
Annualized volatility is high at 100%, underscoring the risk and potential for sharp moves in either direction.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.08 | $2.13 | $3.15 | 0% | Neutral | |
| $1.84 | $2.51 | $3.70 | +18% | Neutral | |
| $1.68 | $2.44 | $3.82 | +15% | Neutral | |
| $1.83 | $2.78 | $4.56 | +31% | Bullish | |
| $1.51 | $2.40 | $4.10 | +13% | Neutral | |
| $1.49 | $2.46 | $4.35 | +16% | Neutral | |
| $2.12 | $3.65 | $6.64 | +72% | Bullish | |
| $2.30 | $4.11 | $7.68 | +93% | Bullish | |
| $2.33 | $4.31 | $8.26 | +103% | Bullish | |
| $2.31 | $4.44 | $8.69 | +109% | Bullish | |
| $3.16 | $7.02 | $15.07 | +230% | Bullish | |
| $4.79 | $10.65 | $24.50 | +401% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.08 | $2.13 | $2.62 | +0.00% |
| August 2026 | $1.89 | $2.29 | $2.88 | +7.64% |
| September 2026 | $1.96 | $2.40 | $3.08 | +5.07% |
| October 2026 | $1.88 | $2.33 | $3.04 | -3.15% |
| November 2026 | $1.82 | $2.28 | $3.01 | -2.25% |
| December 2026 | $1.86 | $2.35 | $3.15 | +3.45% |
Click any year to see its month-by-month ALXO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ALXO to range from $1.08 to $3.15 through 2026. The $2.13 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ALXO price prediction for 2027 points to an average of $2.51 (low $1.84, high $3.70) — a potential gain of +18% on today's $2.13. Price action looks broadly range-bound.
In 2028, ALXO is projected to trade between $1.68 and $3.82, averaging $2.44 — a potential gain of +15% from today's $2.13. That is -3% versus the projected 2027 average. A consolidation phase looks the most probable path here.
ALX Oncology Holdings Inc.'s 2029 outlook centres on $2.78, within a $1.83 to $4.56 range. That is up +14% on the projected 2028 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2030, ALXO could reach as high as $4.10, with a base case around $2.40 and support toward $1.51 — roughly +13% from $2.13. A consolidation phase looks the most probable path here.
Expect ALXO to range from $1.49 to $4.35 through 2031. The $2.46 average target implies a +16% move from current prices. That is up +3% on the projected 2030 average. Price action looks broadly range-bound.
The ALXO price prediction for 2032 points to an average of $3.65 (low $2.12, high $6.64) — a potential gain of +72% on today's $2.13. Buyers look set to stay in control over this stretch.
In 2033, ALXO is projected to trade between $2.30 and $7.68, averaging $4.11 — a potential gain of +93% from today's $2.13. That is up +13% on the projected 2032 average. Momentum favours further upside here.
ALX Oncology Holdings Inc.'s 2034 outlook centres on $4.31, within a $2.33 to $8.26 range. That is up +5% on the projected 2033 average. That marks a +103% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ALXO could reach as high as $8.69, with a base case around $4.44 and support toward $2.31 — roughly +109% from $2.13. Momentum favours further upside here.
Expect ALXO to range from $3.16 to $15.07 through 2040. The $7.02 average target implies a +230% move from current prices. That is up +58% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ALXO price prediction for 2050 points to an average of $10.65 (low $4.79, high $24.50) — a potential gain of +401% on today's $2.13. Momentum favours further upside here.
Investing $1,000 in ALXO today (≈ 470.588235 ALXO) could be worth
$5,013.6
+$4,013.6 (+401%) by 2050 · US Dollar
Based on the average projected ALXO price of $10.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALXOwould be worth at today's price.
$1,000 invested in ALXO on Jul 10, 2025 (≈ 2,012.072399 ALXO) would be worth
$4,275.65
+$3,275.65 (+327.6%) today · 4.28× · US Dollar
Based on a ALXO entry price of $0.497 vs. today's $2.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.07 | $1,026.57 | +2.7% |
| 1 month ago | $1.46 | $1,455.48 | +45.5% |
| 3 months ago | $1.7 | $1,250 | +25.0% |
| 6 months ago | $1.44 | $1,475.69 | +47.6% |
| 1 year ago | $0.497 | $4,275.65 | +327.6% |
| All time (5.0y) ago | $54.77 | $38.8 | -96.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALXO forecast.
Our base-case forecast reaches $4.30 around 2034.
Implied market cap at $4.30: $578.62M
The multi-year forecast points to a path of gradual, then accelerating growth in the price trajectory, with notable milestones in the 2030s and beyond. By 2030, the average price is forecast to be $2.29 with an ROI of 11.1%. The 2032–2035 period shows meaningful upside, with 2032 Avg $3.49 and ROI 69.3%, 2033 Avg $3.92 and ROI 90.4%, 2034 Avg $4.12 and ROI 100.1%, and 2035 Avg $4.24 and ROI 105.9%.
The acceleration continues into the 2040s, with 2040 Avg $6.68 and ROI 224.2%, and culminates in 2050 with Avg $10.05 and ROI 388%. These figures reflect a long-run expansion in value, supported by the higher-end projections for later years.
These are estimates, not guarantees. The forecast depicts a wide range of outcomes and relies on market and company-specific variables continuing in ways that may not occur, alongside a backdrop of high volatility (annualized volatility listed at 100%). Investors should consider the potential for substantial upside as well as meaningful downside risk.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $2.29 with a 11.1% ROI; the range for 2030 is not specified beyond the min of $1.43 and max of $3.94.
Forecasts indicate potential upside over the long term, with 2040 and 2050 averages at $6.68 and $10.05 respectively and ROIs of 224.2% and 388%. However, the 2026 average is $2.06 with 0% ROI, and the forecast includes a wide range of outcomes and high volatility, so these are estimates, not guarantees.
The forecast shows 2040 average at $6.68 and 2050 average at $10.05, with earlier years like 2032–2035 below $5 on average. A move above $5 appears in the 2040s based on the provided averages.
Current price is $2.06.
The 30-day range is from $1.46 up to $2.90.
ALX Oncology Holdings Inc. Community Discussion
0Share your ALX Oncology Holdings Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.